JPRN-jRCT2080223109已完成1 期
A Phase I study of ET-743 in combination with pegylated liposomal doxorubicin (PLD) in patients with advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Patients who provided written informed consent to participate as subjects of this study
- •- Patients who have histologically or cytologically proven epithelial ovarian, primary peritoneal, or fallopian tube cancer
排除标准
- •- Patients with severe diseases or medical conditions
研究者
相似试验
进行中（未招募）
1 期
EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate CancerMetastatic castration-resistant prostate cancerMedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2023-509336-25-00Essa Pharma Inc.137
未知
2 期
Safety assessment study of ET-743 in patients with translocation-related sarcomasPatients with malignant soft tissue sarcomas of histological types that have been reported to carry chromosomal translocationsJPRN-jRCT2080222464Taiho Pharmaceutical Co., Ltd.50
未知
1 期
Phase 1b study of U3-1287 in combination with erlotinib in subjects with advanced non-small cell lung cancer (NSCLC)JPRN-jRCT2080221467DAIICHISANKYO Co.,Ltd.36
未知
2 期
Phase II study of ET-743 in patients with translocation-related sarcomasJPRN-jRCT2080221808Taiho Pharmaceutical Co., Ltd.74
未知
2 期
A Phase 2B/3 Open-label Study of EPI-743 in Children with Leigh SyndromeJPRN-jRCT2080222300Sumitomo Dainippon Pharma Co., Ltd.5